Keywords: GlaxoSmithKline, Zunrisa, EMEA, MA withdrawal
GlaxoSmithKline withdraws European MA for nausea drug Zunrisa
Article | 14 October 2009
UK drug giant GlaxoSmithKline has told the European Medicines Agency (EMEA) that it is withdrawing its application for a centralized marketing authorization for Zunrisa (casopitant mesilate), 50mg and 150mg film coated tablets, in what it described as “a difficult decision.” Zunrisa was expected to be used in the prevention of post-operative nausea and vomiting and chemotherapy-induced nausea and vomiting.
The MA application for Zunrisa was submitted to the Agency on July 2, 2008. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
